Perspective on Broadly neutralizing Antibodies
HIV-1 Spike Protein, Showing Sites Targeted by Broadly Neutralizing Monoclonal Antibodies.
The inset shows the virus with its surface spikes. The left panel shows target sites of monoclonal antibodies in clinical development. The right panel illustrates the binding of four different broadly neutralizing antibodies.
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy
Caskey M., Klein F., Nussenzweig M.C.
Despite tremendous efforts to prevent transmission of human immunodeficiency virus type 1 (HIV-1), new infections and AIDS-related deaths continue to be a global problem. Antiretroviral therapy (ART) can effectively suppress HIV-1 replication and limit disease progression. However, ART fails to eradicate the virus, and suppression requires lifelong therapy, which may have side effects and poses a risk of the development of resistance. New approaches to preventing and treating HIV-1 infection are therefore necessary to contain the epidemic and to bolster nascent efforts to find a cure. N Eng J Med, 11/9/2016